Aposense Ltd.: Clinical Trials

4 trials sponsored by Aposense Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Unknown 2, Completed 1, Terminated 1

Follow Aposense Ltd.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation
[18F]-ML-10 in conjunction with PET imaging - Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Phase 2UnknownAposense Ltd.602010-12-012010-12-17
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10), Stereotactic Radio-Surgery (SRS) therapy, Positron Emission Tomography - Brain Metastases, Solid Tumors
Phase 2UnknownAposense Ltd.302008-11-012010-05-12
18F ML-10 for Early Detection of Response of Brain Metastases to SRS
([18F]-ML-10) - Metastasis to Brain of Unknown Primary
Phase 2TerminatedAposense Ltd.12008-07-012013-02-15
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
18F ML-10 - Solid Tumors, Brain Metastases
Phase 2CompletedAposense Ltd.102008-03-012013-02-13

Conditions studied

Brain Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Head and Neck Neoplasms (1)

Interventions

5-fluoropentyl-2-methylmalonic acid (4)  ·  Magnetic Resonance Spectroscopy (2)  ·  Spermine Synthase (1)  ·  Therapeutics (1)

Countries

United States (2)

Top investigators

Aaron Allen, M.D. (1)  ·  Aaron Allen, MD (1)  ·  David Sher, MD, MPH (1)  ·  Heron Dwight, MD (1)  ·  Yael Cohen (1)